Table 4.
Oncological and functional outcome divided in age groups
| Characteristic | Age 39–59 year | Age 60–74 year | P value |
|
|---|---|---|---|---|
| Adverse Pathology | no. (%) | no. (%) | ||
| pT3 and/or Gleason score > 7 | 40/121 (33.0) | 75/212 (35.4) | 0.720 | |
| pT3 | 10/121 (8.3) | 17/212 (8.0) | 1.000 | |
| Gleason ≥ 7 | 36 (29.8) | 69 (32.6) | ||
| Gleason score 3+4 = 7 | 30/36 (24.8) | 59/69 (27.8) | 0.841 | |
| Gleason score 4+3 = 7 | 6/36 (5.0) | 10/69 (4.7) | ||
| Gleason score ≥ 8 | 0/36 (0.0) | 0/69 (0.0) | ||
| Surgical margin status | ||||
| Negative | 101/119 (84.9) | 174/210 (82.9) | 0.757 | |
| Positive | 18/119 (15.1) | 36/210 (17.1) | ||
| Surgical margin status pT2 | ||||
| Negative | 95/109 (87.2) | 165/193 (85.5) | 0.732 | |
| Positive | 14/109 (12.8) | 28/193 (14.5) | ||
| Surgical margin status pT3 | ||||
| Negative | 6/10 (60.0) | 9/17 (53.0) | 1.000 | |
| Positive | 4/10 (40.0) | 8/17 (47.0) | ||
| PSA > 0.1 (ng/l) 6–12 weeks postoperative | ||||
| Yes | 3/120 (2.5) | 4/209 (1.9) | 0.709 | |
| No | 117/120 (97.5) | 205/209(98.1) | ||
| BCR (PSA ≥ 0.25 ng/l) or radiotherapy at 12 months | ||||
| Yes | 4/123 (3.2) | 4/211 (1.9) | 0.507 | |
| No | 119/123 (97.8) | 207/211 (98.1) | ||
| Neurovascular bundle preservation | ||||
| Bilateral, both sides interfascial or intrafascial dissection | 102/124 (82.3) | 140/213 (65.7) | <0.001 | |
| Unilateral | 18/124 (14.5) | 36/213 (16.9) | ||
| None | 4/124 (3.2) | 37/213 (16.9) | ||
| Erectile function (IIEF > 21) reported by patients 12 months after surgery | ||||
| IIEF > 21a | 16/59 (27.1) | 17/62 (27.4) | 1.000 | |
| Erectile function (IIEF question 3 ≥ about half the time) reported by patients 12 months after surgery | ||||
| IIEF question 3 (≥ about half the time)b | 34/74 (46.0) | 48/98 (49.5) | 0.759 | |
| Urinary continence (Pad-free) reported by patients 12 months after surgery | ||||
| Pad-freec | 65/81 (80.2) | 89/124 (71.8) | 0.189 | |
| Urinary continence (Pad-free and leakage free) reported by patients 12 months after surgery | ||||
| Pad-free and leakage freed | 36/71 (50.7) | 59/107 (55.1) | 0.646 | |
| Urinary continence (Change of pad less than once per 24 hours) reported by patients 12 months after surgery | ||||
| Change of pad less than once per 24 hourse | 75/81 (92.6) | 106/125 (84.8) | 0.126 | |
|
Potent and Continent at 12 monthsf Potent IIEF question 3 (≥ about half the time) + continent (Change of pad less than once per 24 hours) |
||||
| Yes | 36/87 (41.4) | 50/134 (37.3) | 0.574 | |
| No | 51/87 (58.6) | 84/134 (62.7) | ||
| Trifecta at 12 monthsg | ||||
| Yes | 34/87 (39.1) | 50/134 (37.3) | 0.887 | |
| No | 53/87 (60.9) | 84/134 (62.7) | ||
Patients with preoperative IIEF > 21 and bilateral nerve-sparing during RP
Patients with preoperative IIEF Q3 (≥ about half the time) and bilateral nerve –sparing
Patients with preoperative Pad-free continence and bilateral nerve-sparing
Patients with preoperative Pad-free and leakage-free continence and bilateral nerve-sparing
Patients with preoperative Change of pad less than once per 24 hours and bilateral nerve-sparing
Patients preoperative potent (≥ about half the time) + continent (Change of pad less than once per 24 hours)
BCR-free or No local recurrence or no RT + potent (≥ about half the time) + continent (Change of pad less than once per 24 hours) among preoperative potent and continent patients.